Study Summary
This trial is testing whether adding pembrolizumab and/or olaparib to standard radiation therapy can improve outcomes for patients with TNBC.
- Metastatic Breast Cancer
- Breast Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 8 weeks from baseline
Trial Safety
Safety Progress
Side Effects for
Trial Design
4 Treatment Groups
Arm B
1 of 4
Arm A
1 of 4
Arm B (the study is amended to pause Arm B)
1 of 4
Arm C (activate new arm)
1 of 4
Experimental Treatment
34 Total Participants · 4 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What are the approved indications for Pembrolizumab?
"Pembrolizumab is frequently used to treat patients with melanoma that cannot be surgically removed. It can also help those at high risk for recurrence or microsatellite instability disease." - Anonymous Online Contributor
How many people are taking part in this experiment at most?
"That is correct. The clinical trial, which has been recruiting since April 21st 2021, is looking for 34 patients to enroll at 7 different sites." - Anonymous Online Contributor
How many different research facilities are overseeing this experiment?
"There are 7 primary centres for this study, with Memorial Sloan Kettering Bergen (Limited Protocol Activities) in Montvale, Memorial Sloan Kettering Commack (Limited Protocol Activities) in Commack, and Memorial Sloan Kettering Cancer Center (All Protocol Activities) in New York being a few of them." - Anonymous Online Contributor
Are patients currently being recruited for this trial?
"Yes, the information available on clinicaltrials.gov indicates that this trial is still actively recruiting patients. The study was first posted on 4/21/2021 and has since been updated on 10/19/2022. Currently, the research team is looking for 34 individuals from 7 different centres." - Anonymous Online Contributor
Has this clinical trial been done before?
"Pembrolizumab has been the subject of 1162 studies since 2005, with the first being a Phase 1 drug approval stage study sponsored by AstraZeneca. This original trial had 98 participants and was conducted across 66 countries in 3072 cities. 377 follow-up studies have been completed." - Anonymous Online Contributor
When did the FDA last greenlight pembrolizumab?
"Pembrolizumab falls into the Phase 2 category, meaning that while there is some evidence pointing to its safety, there is none yet suggesting that it is an effective treatment. Our team at Power gave it a score of 2." - Anonymous Online Contributor
Are there Pembrolizumab studies that have been completed in the past?
"1162 clinical trials involving Pembrolizumab are ongoing. Of these, 143 have reached Phase 3 status. The majority of these studies are based out of Houston, Texas; however, there are 43122 different locations running Pembrolizumab trials." - Anonymous Online Contributor